{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"All Grade 3-4 Cardiovascular events based on CTCAEv2 as reported on case report forms.","groups":[{"description":"Pre-irradiation induction therapy (wks 1-6); Chemoradiation induction therapy (wks 7-12); Post-radiation induction therapy (wks 13-18); Maintenance therapy (wks 19-44); Continuation therapy (wks 45-51)\n\nInduction Chemotherapy: CT backbone of the IRS-III regimen \\[vincristine, dactinomycin, cyclophosphamide (specifically, in combination), cisplatin, doxorubicin, and imidazole carboximide (DTIC)\\] was modified to incl temozolomide in lieu of DTIC. Pts w/ M0 dz (and initially positive CSF cytology) rcvd intrathecal (IT) CT (alt btwn intralumbar and intraventricular routes) w/ methotrexate, cytarabine, and hydrocortisone, coinciding with a cycle of CT.\n\nRadiation Therapy: Pts w/ M0 dz OR M+ dz aged \\<3y received focal RT (3D conformal or intensity-modulated delivery). Pts \\>3y w/ M+ dz rcvd craniospinal irradiation.\n\nContinuation Therapy: Pts treated with either non-doxorubicin or doxorubicin dose therapy if receiving CSI or mediastinal radiotherapy or not, respectively.\n\nfilgrastim","id":"OG000","title":"Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)"}],"paramType":"NUMBER","populationDescription":"The analysis population excludes 1 patient who withdrew before treatment.","reportingStatus":"POSTED","timeFrame":"Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.","title":"Grade 3-4 Cardiovascular Events","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"adverse events"}